IOVS British Journal of Pharmacology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Milz, S.
Right arrow Articles by Benjamin, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Milz, S.
Right arrow Articles by Benjamin, M.
(Investigative Ophthalmology and Visual Science. 2002;43:1330-1334.)
© 2002 by The Association for Research in Vision and Ophthalmology, Inc.

Expression of a Wide Range of Extracellular Matrix Molecules in the Tendon and Trochlea of the Human Superior Oblique Muscle

Stefan Milz1,2, Frank Regner1,2, Reinhard Putz3 and Michael Benjamin3

1 From the Department of Anatomy, Ludwig-Maximilians-University, Munich, Germany; and the 2 Anatomy Unit, School of Biosciences, University of Wales Cardiff, Cardiff, Wales.


   Abstract
Top
 Abstract
Introduction
 Methods
 Results
 Discussion
 References
 
PURPOSE. To show that the molecular composition of the extracellular matrix of the trochlea and its associated tendon may explain the link between some cases of acquired Brown syndrome and rheumatoid arthritis.

METHODS. One trochlea and its tendon from 11 dissecting-room cadavers were fixed in methanol, cryosectioned, and immunolabeled with a panel of monoclonal antibodies against types I, II, III, V, and VI collagens, chondroitin-4 and -6, keratan and dermatan sulfates, aggrecan, link protein, versican, and tenascin. Labeling was detected with an avidin-biotin-peroxidase detection kit.

RESULTS. The trochlea had a central core of hyaline cartilage surrounded by a band of fibrocartilage, but the tendon had no cartilage cells. Significantly, however, both structures immunolabeled for aggrecan, link protein, and type II collagen—molecules typical of articular cartilage.

CONCLUSIONS. The presence of aggrecan, link protein, and type II collagen may account for the coincidence between transient attacks of acquired Brown syndrome in patients with juvenile and adult forms of chronic rheumatoid arthritis. Cleavage of aggrecan by aggrecanase in articular cartilage characterizes cartilage degeneration in rheumatoid arthritis. Thus, it is possible that aggrecan cleavage also occurs in the trochlea and tendon and contributes to their degeneration or to a local inflammatory reaction that may swell and thicken the tendon. In this context, it is also significant that link protein and type II collagen are now regarded as relevant antigenic targets for autoimmune responses in rheumatoid arthritis.


   Introduction
Top
 Abstract
 Introduction
Methods
 Results
 Discussion
 References
 
The tendon of the superior oblique muscle changes its direction of pull by wrapping around a fibrocartilaginous pulley (the trochlea) attached to the medial wall of the orbit. A loss of function in this region impairs the ability of a patient to elevate the eye in adduction—a condition known as Brown syndrome, or superior oblique tendon sheath syndrome.1 2 3 4 Although the trochlea is frequently described as cartilaginous5 6 or fibrocartilaginous,7 8 9 little is known of its molecular composition or that of the tendon itself. Such information is important to establish, however, because of the link that is now known to exist between the acquired form of Brown syndrome and rheumatoid arthritis (RA).10 11 12 13 14 15 In some patients with RA, there is an autoimmune response against aggrecan, link protein, and type II collagen.16 17 18 19 Herein, we argue that if such molecules are also present in the trochlea and/or tendon, it may explain the connection between the diseases. Significantly in this connection, the transverse ligament of the atlas contains all these molecules and can also be affected by RA with an autoimmune response.21 Similar to the tendon of the superior oblique muscle, this ligament is subject to both compressive and tensile loading as it changes direction by wrapping around a pulley—the dens. The purpose of the present study therefore was to provide an immunohistochemical profile of the superior oblique tendon and its trochlea, using a wide range of antibodies directed against molecules found in the extracellular matrix (ECM) of connective tissues, including cartilage.


   Methods
Top
 Abstract
 Introduction
 Methods
Results
 Discussion
 References
 
Tissue Preparation
The trochlea and its associated tendon were removed from 11 unfixed human cadavers (both sexes; ages 17–39 years) within 36 hours of death and fixed for 24 hours in 90% methanol at 4°C. Institutional Review Board and Ethics Committee approval was not required for this study, because all human material was obtained from bodies donated to the Department of Anatomy at Munich University for research purposes, before death. The protocol adhered to the tenets of the Declaration of Helsinki for research involving human tissue.

Immunohistochemical Procedures
Details of the immunohistochemical procedures have been published previously,20 21 but briefly, the procedure was as follows. Specimens were stored at -20°C as necessary, rinsed in phosphate-buffered saline (PBS), infiltrated overnight with 5% sucrose in PBS, and cryosectioned at 12 µm. Sections were stained with toluidine blue to highlight the presence of any cartilage and fibrocartilage by its metachromasia and with a panel of monoclonal antibodies (Table 1) . The antibodies were directed against collagens (types I, II, III, V, VI), glycosaminoglycans (GAGs; chondroitin-4 and -6-sulfates, dermatan sulfate and keratan sulfate), and proteoglycans (versican, tenascin, together with aggrecan and its link protein). Sections immunolabeled for aggrecan and for link protein were treated with 10 mM dithiothreitol in 50 mM Tris-HCl and 200 mM sodium chloride (pH 7.4) for 2 hours at 37°C and then alkylated with 40 mM iodoacetamide in PBS for 1 hour at 37°C. The sections were subsequently incubated at 37°C with chondroitinase AC (0.25 U/mL; Sigma, Diesenhofen, Germany). Endogenous peroxidase activity was blocked in all sections by pretreatment with 0.3% hydrogen peroxide in methanol for 30 minutes and nonspecific binding of the secondary antibody was reduced with an appropriate serum block for 40 minutes. We controlled for nonspecific binding of antibodies by omitting the primary antibody or by incubating the sections with normal mouse immunoglobulins (5 µg/mL for all monoclonal antibodies). Antibody binding was detected with an avidin-biotin-peroxidase complex kit (Vectastain ABC Elite; Vector Laboratories, Burlingame, CA).


View this table:
[in this window]
[in a new window]
  		Table 1. Primary Antibodies Used for Immunohistochemistry

 
Monoclonal Antibodies
The monoclonal antibodies CIICI,22 5C6,30 and 12C5,23 28 were obtained from the Developmental Studies Hybridoma Bank maintained by the Department of Biological Sciences, University of Iowa (under contract NO1-HD-7-3263 from the National Institute of Child Health and Human Development [NICHD], Bethesda, MD).


   Results
Top
 Abstract
 Introduction
 Methods
 Results
Discussion
 References
 
The tendon was largely fibrous (Fig. 1a) and separated from the trochlea by a bursa (Fig. 1b) . Although the tendon had no obvious fibrocartilage cells, its ECM was slightly metachromatic, especially near the surface where it faces the trochlea. The latter varied greatly in appearance from the center to the periphery. Its central part more closely resembled hyaline cartilage, but its periphery was more fibrocartilaginous (Figs. 1c d e) . The immunolabeling characteristics of the tendon and trochlea are summarized in Table 2 . No labeling was seen in any of the control sections.



View larger version (212K):
[in this window]
[in a new window]
  		Figure 1. Immunohistochemical labeling of the trochlea and superior oblique tendon for collagens. (a) Uniform labeling for type VI collagen in the tendon. The elongated shape of the nuclei (arrow) shows that the tendon has no fibrocartilage cells. (b) The bursa (arrows) between the trochlea (TR) and the tendon (TE) in a section labeled for type VI collagen. Note the pronounced pericellular staining in the trochlea. High- (c) and low- (d) power views of the trochlea showing the presence of type I collagen in both the hyaline (HC) and fibrocartilage (FC) regions. (d) Highlight of the variability in labeling within the zone of hyaline cartilage. Rectangle: region corresponding to the field shown in (c). P, perichondrium. (e) Type II collagen labeling in the trochlea in a neighboring section to that illustrated in (c) and imaged at the same magnification. Note the complimentary pattern of staining in (c) and (e). Only the hyaline cartilage (HC) zone labeled for type II collagen and the fibrocartilage (FC) was unlabeled. (f) Localized labeling for type II collagen in the tendon (arrows), near the contact zone with the trochlea. Dotted line: border between the tendon (TE) and the trochlea (TR). Scale bars: (a, d) 100 µm; (b) 500 µm; (c, e, f) 50 µm.

 

View this table:
[in this window]
[in a new window]
  		Table 2. Summary of the Immunolabelling Characteristics of the Tendon of the Superior Oblique Muscle and the Trochlea

 
Collagens
Types I, III, and VI collagens were found in all regions of the tendon (Figs. 1a 1b 1c 1d) . However, labeling for types I and II collagen varied substantially in different parts of the trochlea. Both the peripheral region of fibrocartilage and the outer parts of the zone of hyaline cartilage in the trochlea labeled for type I collagen, but the inner part of the hyaline cartilage zone did not (Figs. 1c 1d) . In contrast, labeling for type II collagen was absent from the fibrocartilage (compare Figs. 1c 1e ) and present throughout the zone of hyaline cartilage. Local patches of type II collagen labeling were seen in the tendon in 7 of the 11 specimens (Fig. 1f) . Although there was no difference in the labeling intensity for type VI collagen in the different parts of the tendon, labeling was more pericellular in the trochlea (Fig. 1b) .

Glycosaminoglycans and Proteoglycans
With the exception of a single specimen that failed to label for keratan sulfate, all the trochleae examined labeled for all GAGs (Figs. 2a 2b 2c 2d) . Aggrecan and link protein were more prominent in the center of the trochlea and most evident pericellularly (Figs. 2e 2f 2g 2h) . In some specimens where there were large cartilage cells in the center of the tissue, labeling for versican was absent in the territorial and interterritorial matrix (Fig. 2i) . There was greater variability in GAG and proteoglycan (PG) labeling between tendons. Chondroitin-6-sulfate (Figs. 2a 2b) and particularly keratan sulfate (Figs. 2c 2d) were less commonly detected in tendons than in their pulleys, but tenascin and versican were present in most tendons (Fig. 2j) . Aggrecan was seen in 10 of the 11 tendons (Fig. 2f) , but link protein was detected in all (Fig. 2h) .



View larger version (171K):
[in this window]
[in a new window]
  		Figure 2. Immunohistochemical labeling of the trochlea and superior oblique tendon for GAGs and proteoglycans. Chondroitin-6-sulfate in the trochlea (a) and tendon (b). Keratan sulfate labeling in the trochlea (c) and tendon (d). Aggrecan in the trochlea (e) and tendon (f). Note the more pronounced labeling in the hyaline cartilage (HC) region of the trochlea than in the peripheral fibrocartilage (FC) zone. Link protein in the trochlea (g) and tendon (h). As with aggrecan, labeling was more pronounced in the former. Versican labeling in the trochlea (i) and tendon (j). Note uniform labeling in the tendon, but patchy labeling in the trochlea (i, arrows). Scale bars, 50 µm.

 

   Discussion
Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
References
 
The results show that the trochlea is a mixture of fibrocartilage and hyaline cartilage and that the superior oblique tendon has a fibrous morphology but a profile of ECM molecules more typical of fibrocartilage.20 21 31 32 33 Biomechanical data suggest that during adduction-elevation of the eye, the superior oblique muscle generates a force of 17.4 g and that its tendon has a longitudinal excursion of approximately 5.6 mm as it slides through the trochlea.34 According to Helveston et al.,35 the longitudinal excursion of the central part of the tendon is greater than the remainder and may reach 8 mm. The values are only slightly lower for isolated elevation (12.7g and 4.1 mm34 ). However, under conditions of tetanic stimulation, forces may reach 40 to 100g.34 36 Because the angle through which the tendon changes direction is steep (53°), such forces may be enough to trigger the production of some molecules typical of a fibrocartilaginous ECM near its articulating-sliding surface.

The absence of fibrocartilage cells in the superior oblique tendon clearly contrasts with their presence in many of the large tendons that wrap around bony pulleys in the foot (e.g., peroneus longus33 ). The absence of typical fibrocartilage from the tendon makes sense biomechanically, in that the central part of the tendon is more mobile than the remainder,35 and its fascicles must thus slide over each other for any relative movement to occur. Such a sliding of tendon fascicles would be impossible in many of the fibrocartilaginous tendons of the foot, because their parallel fascicle arrangement is interrupted as the collagen fibers become interwoven in basket-weave fashion.33 This may therefore be why the superior oblique tendon is fibrous and does not have any typical basket-weave complex of collagen fibers seen elsewhere.

The movement of the tendon in the trochlear region is compromised in Brown syndrome, often necessitating surgical treatment.37 38 39 40 In such cases, the most prominent features are deficient elevation in adduction and positive forced motions for both elevation in adduction and excyclotortion of the globe.3 8 41 42 Although this pattern of ocular deviation is congenital in many patients,43 44 there is also a rare form of acquired Brown syndrome that is associated with RA.45 46 47 48 However, the etiology of this acquired condition is unclear. Although it has long been known that autoantibodies against a 23-kDa protein of human fibroblasts arise in Graves disease,49 evidence has only recently accumulated to suggest that Brown syndrome can also be an autoimmune condition. It is suggested that the trochlea and its tendon may be a target for autoantibodies produced in patients with RA (for reviews see Refs. 3 50 This may occur in both the juvenile12 51 and the adult10 11 forms of the disease. It is also possible, however, that some forms of acquired Brown syndrome may simply be cases of stenosing tenosynovitis in which tendon thickening prevents free excursion through the trochlea.43

In view of the association between acquired Brown syndrome and RA, it is important to note that aggrecan and link protein are consistently present in the trochlea and are generally also present at the sliding surface of the tendon. Aggrecan is the large aggregating proteoglycan that is responsible for the compression-tolerance properties of articular cartilage,53 and link protein is an extracellular glycoprotein that stabilizes the interaction between aggrecan and hyaluronan.54 55 The two epitopes recognized by the monoclonal antibody 8A4 for link protein lie in the tandem-repeat domains that are involved in hyaluronan interactions. In articular cartilage, it is the high charge density of sulfated GAGs in aggrecan that attracts water into the tissue. The aggrecan and water are then held in place by the fibrous network of type II collagen.56

To our knowledge, this is the first time that aggrecan and link protein have been demonstrated in the human trochlea. The significance of the finding relates to clinical observations that report a coincidence between transient attacks of acquired Brown syndrome in patients with juvenile and adult forms of chronic RA.13 51 Because cleavage of aggrecan by aggrecanase in articular cartilage is a characteristic feature of cartilage degeneration in RA,57 58 it seems possible that such cleavage occurs in the trochlea and perhaps in the tendon as well. This would contribute to the degeneration of these structures or at least to a local inflammatory reaction that may cause swelling and thickening of the tendon. It is significant therefore that link protein is now also regarded as one of the major antigenic targets for autoimmune responses in juvenile and adult RA.16 17 18 Because RA is a systemic disease predominantly affecting tissues with a cartilage phenotype and because the trochlea immunolabels strongly for link protein, aggrecan, and collagen type II (which is also a major target in RA19 ), this region should also be regarded as a preferred target for inflammatory reactions. Thus, in the course of the disease, the trochlea might be expected to lose its mechanical function of promoting free tendon movement more readily than if it were pure fibrous tissue instead. The partial disappearance of enthesis fibrocartilage in patients with RA has already been reported at the attachment of the central slip of the extensor tendon to the intermediate phalanx.50


   Footnotes
 
2 Contributed equally to this investigation, which is part of the doctoral thesis of FR. The results are published with permission of the Medical Faculty of the Ludwig-Maximilians University, Munich. Back

Supported by the Friedrich Baur Stiftung, Munich.

Submitted for publication July 24, 2001; revised December 11, 2001; accepted December 20, 2001.

Commercial relationships policy: N.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Corresponding author: Stefan Milz, Anatomische Anstalt, Ludwig-Maximilians-Universität, Pettenkoferstr.11, D-80336 München, Germany; stefan.milz{at}anat.med.uni-muenchen.de.


   References
Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 

  1. Brown, HW. (1950) Congenital structural muscle abnormalities Allen, JH eds. Strabismus Ophthalmic Symposium ,205-236 Mosby St. Louis.
  2. Catford, GV, Hart, JC. (1971) Superior oblique tendon sheath syndrome: an electromyographical study Br J Ophthalmol 55,155-160[Free Full Text]
  3. Wilson, ME, Eustis, HS, Jr, Parks, MM. (1989) Brown’s syndrome Surv Ophthalmol 34,153-172[Medline][Order article via Infotrieve]
  4. Hadjadj, E, Conrath, J, Ridings, B, Denis, D. (1998) Syndrome de Brown: actualites J Fr Ophtalmol 21,276-282[Medline][Order article via Infotrieve]
  5. Hyrtl, J. (1863) Lehrbuch der Anatomie des Menschen Wien:Braumüller ,541-543
  6. Sevel, D. (1986) The origins and insertions of the extraocular muscles: development, histologic features, and clinical significance Trans Am Ophthalmol Soc 84,488-526[Medline][Order article via Infotrieve]
  7. Testut, L, Jacob, O. (1905) Traite d’Anatomie Topographique avec Applications Medico-Chirurgicales ,401-402 O. Doin Paris.
  8. Lang, J, Wachsmuth, W. (1979) v Lanz, T Wachsmuth, W eds. Praktische Anatomie, Erster Band, Erster Teil, Kopf, Teil B, Gehirn und Augenschädel ,494-496 Springer Berlin.
  9. Williams, PL, Bannister, LH, Berry, MM, et al (1995) Gray’s Anatomy 38th ed. Churchill-Livingstone Edinburgh.
  10. Mortensen, TM, Fano, N, Madsen, PH. (1998) Browns syndrom hos en voksen patient med morbus Still Ugeskr Laeger 160,3084-3085[Medline][Order article via Infotrieve]
  11. Olivares, JP, Schiano, A, Bardot, A, Santini, R. (1988) Acquired Brown syndrome: an unusual complication of rheumatoid polyarthritis (letter) Rev Rhum Mal Osteoartic 55,1035
  12. Roifman, CM, Lavi, S, Moore, AT, Morin, DJ, Stein, LD, Gelfand, EW. (1985) Tenosynovitis of the superior oblique muscle (Brown syndrome) associated with juvenile rheumatoid arthritis J Pediatr 106,617-619[Medline][Order article via Infotrieve]
  13. Beck, M, Hickling, P. (1980) Treatment of bilateral superior oblique tendon sheath syndrome complicating rheumatoid arthritis Br J Ophthalmol 64,358-361[Free Full Text]
  14. Sandford-Smith, JH. (1969) Intermittent superior oblique tendon sheath syndrome Br J Ophthalmol 53,412-417[Free Full Text]
  15. Sandford-Smith, JH. (1975) Superior oblique tendon sheath syndrome Br J Ophthalmol 59,385-386[Abstract/Free Full Text]
  16. Guerassimov, A, Duffy, C, Zhang, Y, et al (1997) Immunity to cartilage link protein in patients with juvenile rheumatoid arthritis J Rheumatol 24,959-964[Medline][Order article via Infotrieve]
  17. Guerassimov, A, Zhang, Y, Banerjee, S, et al (1998) Autoimmunity to cartilage link protein in patients with rheumatoid arthritis and ankylosing spondylitis J Rheumatol 25,1480-1484[Medline][Order article via Infotrieve]
  18. Zhang, Y, Guerassimov, A, Leroux, JY, et al (1998) Induction of arthritis in BALB/c mice by cartilage link protein: involvement of distinct regions recognized by T and B lymphocytes Am J Pathol 153,1283-1291[Abstract/Free Full Text]
  19. Falta, MT, Kotzin, BL. (1998) T Cells as primary players in rheumatoid arthritis Miossec, P van den Berg, WB Firestein, GS eds. T Cells in Arthritis ,201-231 Birkhäuser Basel, Switzerland.
  20. Milz, S, McNeilly, C, Putz, R, Ralphs, JR, Benjamin, M. (1998) Fibrocartilages in the extensor tendons of the interphalangeal joints of human toes Anat Rec 252,264-270[Medline][Order article via Infotrieve]
  21. Milz, S, Schlüter, T, Putz, R, Moriggl, B, Ralphs, JR, Benjamin, M. (2001) Fibrocartilage in the transverse ligament of the human atlas Spine 26,1765-1771[Medline][Order article via Infotrieve]
  22. Holmdahl, R, Rubin, K, Klareskog, L, Larsson, E, Wigzell, H. (1986) Characterization of the antibody response in mice with type II collagen-induced arthritis using monoclonal anti-type II collagen antibodies Arthritis Rheum 29,400-410[Medline][Order article via Infotrieve]
  23. Asher, R, Perides, G, Vanderhaeghen, JJ, Bignami, A. (1991) Extracellular matrix of central nervous system white matter: demonstration of an hyaluronate-protein complex J Neurosci Res 28,410-421[Medline][Order article via Infotrieve]
  24. Caterson, B, Christner, JE, Baker, JR, Couchman, JR. (1985) Production and characterization of monoclonal antibodies directed against connective tissue proteoglycans Fed Proc 44,386-393[Medline][Order article via Infotrieve]
  25. Hedlund, H, Hedbom, E, Heinegard, D, Mengarelli-Widholm, S, Reinholt, FP, Svensson, O. (1999) Association of the aggrecan keratan sulfate-rich region with collagen in bovine articular cartilage J Biol Chem 274,5777-5781[Abstract/Free Full Text]
  26. Caterson, B, Christner, JE, Baker, JR. (1983) Identification of a monoclonal antibody that specifically recognizes corneal and skeletal keratan sulphate: monoclonal antibodies to cartilage proteoglycan J Biol Chem 258,8848-8854[Abstract/Free Full Text]
  27. Calabro, A, Hascall, VC, Caterson, B. (1992) Monoclonal antibodies directed against epitopes within the core protein structure of the large aggregating proteoglycan (aggrecan) from the swarm rat chondrosarcoma Arch Biochem Biophys 298,349-360[Medline][Order article via Infotrieve]
  28. Asher, RA, Scheibe, RJ, Keiser, HD, Bignami, A. (1995) On the existence of a cartilage-like proteoglycan and link proteins in the central nervous system Glia 13,294-308[Medline][Order article via Infotrieve]
  29. Verstraeten, AA, Mackie, EJ, Hageman, PC, et al (1992) Tenascin expression in basal cell carcinoma Br J Dermatol 127,571-574[Medline][Order article via Infotrieve]
  30. Hessle, H, Engvall, E. (1984) Type VI collagen: studies on its localization, structure, and biosynthetic form with monoclonal antibodies J Biol Chem 259,3955-3961[Abstract/Free Full Text]
  31. Benjamin, M, Ralphs, JR. (1997) Tendons and ligaments: an overview Histol Histopathol 12,1135-1144[Medline][Order article via Infotrieve]
  32. Benjamin, M, Ralphs, JR. (1998) Fibrocartilage in tendons and ligaments: an adaptation to compressive load J Anat 193,481-494
  33. Benjamin, M, Qin, S, Ralphs, JR. (1995) Fibrocartilage associated with human tendons and their pulleys J Anat 187,625-633
  34. Robinson, DA. (1975) A quantitative analysis of extraocular muscle cooperation and squint Invest Ophthalmol 14,801-825[Abstract/Free Full Text]
  35. Helveston, EM, Merriam, WW, Ellis, FD, Shellhamer, RH, Gosling, CG. (1982) The trochlea: a study of the anatomy and physiology Ophthalmology 89,124-133[Medline][Order article via Infotrieve]
  36. Collins, CC, Carlson, MR, Scott, AB, Jampolsky, A. (1981) Extraocular muscle forces in normal human subjects Invest Ophthalmol Vis Sci 20,652-664[Abstract/Free Full Text]
  37. Stein, HJ, Pabst, W. (1969) Elektromyographische Untersuchungen zur Pathogenese und Therapie des Musculus obliquus superior-Sehnenscheidensyndroms (Brown-Syndrom) Ber Zusammenkunft Deutsch Ophthalmol Ges 69,618-624
  38. Haworth, SM. (1970) Unusual sequelae of surgery in the superior oblique tendon sheath syndrome Br J Ophthalmol 54,675-679[Free Full Text]
  39. Scott, AB, Knapp, P. (1972) Surgical treatment of the superior oblique tendon sheath syndrome Arch Ophthalmol 88,282-286[Abstract/Free Full Text]
  40. Sprunger, DT, von Noorden, GK, Helveston, EM. (1991) Surgical results in Brown syndrome J Pediatr Ophthalmol Strabismus 28,164-167[Medline][Order article via Infotrieve]
  41. Mühlendyck, H. (1996) Jaensch-Brown-Syndrom: Ursache und operatives Vorgehen Klin Monatsbl Augenheilkd 208,37-47[Medline][Order article via Infotrieve]
  42. Wright, KW. (2000) Results of the superior oblique tendon elongation procedure for severe Brown’s syndrome Trans Am Ophthalmol Soc 98,41-48[Medline][Order article via Infotrieve]
  43. Botelho, PJ, Giangiacomo, JG. (1996) Autosomal-dominant inheritance of congenital superior oblique palsy Ophthalmology 103,1508-1511[Medline][Order article via Infotrieve]
  44. Wright, KW. (1999) Brown’s syndrome: diagnosis and management Trans Am Ophthalmol Soc 97,1023-1109[Medline][Order article via Infotrieve]
  45. Killian, PJ, McClain, B, Lawless, OJ. (1977) Brown’s syndrome: an unusual manifestation of rheumatoid arthritis Arthritis Rheum 20,1080-1084[Medline][Order article via Infotrieve]
  46. Wang, FM, Wertenbaker, C, Behrens, MM, Jacobs, JC. (1984) Acquired Brown’s syndrome in children with juvenile rheumatoid arthritis Ophthalmology 91,23-26[Medline][Order article via Infotrieve]
  47. Kaufman, LD, Sibony, PA, Anand, AK, Gruber, BL. (1987) Superior oblique tenosynovitis (Brown’s syndrome) as a manifestation of adult Still’s disease J Rheumatol 14,625-627[Medline][Order article via Infotrieve]
  48. Knopf, HL. (1989) An unusual case of painful ophthalmoplegia in a patient with rheumatoid arthritis Ann Ophthalmol 21,412-413[Medline][Order article via Infotrieve]
  49. Bahn, RS, Gorman, CA, Johnson, CM, Smith, TJ. (1989) Presence of antibodies in the sera of patients with Graves’ disease recognising a 23 kilodalton fibroblast protein J Clin Endocrinol Metab 69,622-628[Abstract/Free Full Text]
  50. Pittke, EC. (1986) Das Klick-Syndrom der Obliquus-Superior-Sehne und seine Untergruppen Fortschr Ophthalmol 83,518-521[Medline][Order article via Infotrieve]
  51. Kemp, AS, Searle, C, Horne, S. (1984) Transient Brown’s syndrome in juvenile chronic arthritis Ann Rheum Dis 43,764-765[Abstract/Free Full Text]
  52. Sandford-Smith, JH. (1973) Superior oblique tendon sheath syndrome and its relationship to stenosing tenosynovitis Br J Ophthalmol 57,859-865[Free Full Text]
  53. Heinegård, D, Oldberg, O. (1993) Glycosylated matrix proteins Royce, PM Steinmann, B eds. Connective Tissue and its Heritable Disorders ,189-209 Wiley-Liss New York.
  54. Doege, K, Hassell, JR, Caterson, B, Yamada, Y. (1986) Link protein cDNA sequence reveals a tandemly repeated protein structure Proc Natl Acad Sci USA 83,3761-3765[Abstract/Free Full Text]
  55. Goetinck, PF. (1993) Link protein Kreis, T Vale, R eds. Guidebook to the Extracellular Matrix and Adhesion Proteins ,68-72 Oxford University Press Oxford, UK.
  56. Caterson, B, Flannery, CR, Hughes, CE, Little, CB. (1999) Mechanisms of proteoglycan metabolism that lead to cartilage destruction in the pathogenesis of arthritis Drugs Today 35,397-402
  57. Lohmander, LS, Neame, PJ, Sandy, JD. (1993) The structure of aggrecan fragments in human synovial fluid: evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis Arthritis Rheum 36,1214-1222[Medline][Order article via Infotrieve]
  58. Benjamin, M, Ralphs, JR, Shibu, M, Irwin, M. (1993) Capsular tissues of the proximal interphalangeal joint: normal composition and effects of Dupuytren’s disease and rheumatoid arthritis J Hand Surg 18B,371-376[Medline][Order article via Infotrieve]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Milz, S.
Right arrow Articles by Benjamin, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Milz, S.
Right arrow Articles by Benjamin, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS